Liver fibrosis as a barometer of systemic health by gauging the risk of extrahepatic disease

Metabolism and Target Organ Damage, Journal Year: 2024, Volume and Issue: 4(4)

Published: Nov. 15, 2024

This review article proposes the theory that liver fibrosis, abnormal accumulation of excessive extracellular matrix, is not just an indicator disease but also a negative reflection overall systemic health. Liver fibrosis poses heavy financial burden on healthcare systems worldwide and can develop due to chronic from various causes, often sustained inflammation. may generate symptoms become apparent only when it reaches stage cirrhosis associated with clinically significant portal hypertension leads decompensation events or promotes development hepatocellular carcinoma. While viral hepatitis alcohol consumption were once primary causes featuring this role now increasingly taken over by metabolic dysfunction-associated steatotic (MASLD). In MASLD, endothelial dysfunction essential component in pathogenesis, promoting present cells other organs such as heart, lungs, kidneys. Accordingly, predictor liver-related outcomes, well all-cause mortality, cardiovascular risk, extrahepatic cancer. Physicians should be aware individuals seeking medical attention for reasons unrelated health have advanced fibrosis. Early identification these at-risk lead more comprehensive assessment use treatment options, both approved investigational, slow reverse progression

Language: Английский

Nephrological, Pulmonary, and Dermatological Complications in the Context of MAFLD/NAFLD: A Narrative Review

Metabolites, Journal Year: 2025, Volume and Issue: 15(4), P. 272 - 272

Published: April 14, 2025

Background: The most common cause of chronic liver disease is now known to be non-alcoholic fatty (NAFLD), recently redefined as metabolic-associated (MAFLD). This review aims synthesize current evidence on the pathophysiology and clinical implications nephrological, pulmonary, dermatological manifestations among NAFLD/MAFLD patients. In order find safe efficient treatments, has emerged a primary concern for hepatologists worldwide. Methods: We conducted comprehensive literature from major databases, focusing studies that evaluated extrahepatic NAFLD/MAFLD. Emphasis was placed identifying pathophysiological mechanisms assessing their impact renal, systems. Results: Recent developments in management viral hepatitis have lowered mortality rate associated with disease. However, prevalence continues rise, making significant health future. An increasing percentage patients transplant waiting lists cirrhosis hepatocellular carcinoma due Furthermore, incidence kidney surged, linking higher morbidity, mortality, healthcare costs. Conclusions: underdiagnosed underappreciated, yet its rapidly increasing, raising concerns about potential global epidemic. Given multisystemic impact—extending complications—it crucial develop interdisciplinary strategies early detection effective

Language: Английский

NAFLD to MAFLD: collaboration, not confusion - rethinking the naming of fatty liver disease

Metabolism and Target Organ Damage, Journal Year: 2024, Volume and Issue: 4(4)

Published: Dec. 9, 2024

The recent shift from “non-alcoholic fatty liver disease” (NAFLD) and “metabolic associated (MAFLD) to dysfunction-associated steatotic (MASLD) has raised questions about its scientific basis impact on patient understanding. This renaming may create confusion rather than clarity. A collaborative approach involving healthcare professionals, researchers, patients establish terminology that balances accuracy with accessibility is needed. Effective disease naming should be accurate, unique, consistent, objective, accessible - qualities essential for clear communication in healthcare. Disease name more correctness because conventions public use, especially anything related health, must a matter of convenience, ethics, cultural social acceptance. Education straightforward take precedence over renaming, helping providers fully understand the complexities implications treatment. After all, health perspective, MAFLD advantages MASLD.

Language: Английский